financetom
Business
financetom
/
Business
/
Endeavor to sell OpenBet, IMG Arena for about $450 million to management-led group
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Endeavor to sell OpenBet, IMG Arena for about $450 million to management-led group
Nov 11, 2024 2:33 PM

(Reuters) - Endeavor Group ( EDR ) will sell its OpenBet and IMG Arena businesses to management-led group OB Global backed by Hollywood power broker Ari Emanuel for about $450 million, the sports and entertainment company said on Monday.

The deal, which includes participation from OpenBet executives including CEO Jordan Levin, is a "necessary step" for the closing of Endeavor's take-private deal, it said.

Private equity firm Silver Lake in April had struck a $13 billion deal to take Endeavor private. The deal is expected to close by the end of the first quarter of 2025.

OB Global will finance the deal through a mix of cash and debt, Endeavor said. Levin will continue to lead OpenBet, a sports betting entertainment firm, after the deal closes.

"This management buyout allows us to continue executing our vision for increased market expansion and product innovation," Levin said.

Endeavor said it would continue to market IMG Arena for sale to a third-party purchaser prior to and after closing the deal.

IMG Arena delivers live streaming and data feeds for more than 65,000 events across multiple sports.

The transaction is dependent on and expected to close immediately prior to the closing of Endeavor's take-private deal.

Raine Group and Oakvale Capital were the financial advisers to Endeavor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says
Starbucks Faces Near-Term Pressures, But Long-Term Outlook Remains Positive, UBS Says
Apr 23, 2024
03:08 PM EDT, 04/23/2024 (MT Newswires) -- Starbucks' ( SBUX ) 2024 outlook will likely be affected by near-term pressures, but it remains well-positioned in the long term due to strong customer brand affinity and an attractive growth profile, UBS said in a note emailed Tuesday. Challenges in the US stem from protests related to Middle East conflict and pressure...
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Apr 23, 2024
Tuesday, Novartis AG ( NVS )  received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs.  This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugmaker’s Q1 Earnings...
Foreigners add net $32.7 bln to EM portfolios in March -IIF
Foreigners add net $32.7 bln to EM portfolios in March -IIF
Apr 23, 2024
NEW YORK, April 23 (Reuters) - Foreigners added about $32.7 billion to their emerging market portfolios in March, a fifth consecutive month of overall foreign net flows to EMs, the Institute of International Finance said on Tuesday. The IIF banking trade group said flows were positive for both bonds and equities last month, with equities absorbing $10.2 billion and debt...
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Apr 23, 2024
Moderna ( MRNA ) Inc.  is set to clash with Pfizer Inc. ( PFE ) and BioNTech SE in a pivotal London patent trial concerning the development of COVID-19 vaccines.  The High Court is slated to address a legal complaint brought by Moderna ( MRNA ). It alleges patent infringement by its competitors in utilizing the mRNA platform crucial to vaccine development, a claim Pfizer ( PFE ) and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved